In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
How to Empower Lupus Patients Through Social Media & Online Resources
Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…
RheumPAC Supports Rheumatology Through the Pandemic
With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.
State Rheumatology Societies Adjust Meeting Schedules, Formats in Response to COVID-19
Many in-person meetings have been canceled, postponed or moved to virtual formats, likely with lasting economic impacts on state societies.
COVID-19: Practical Tips for Practices
The ACR’s July 13 online town hall, “COVID-19 Guidance for Community Practices,” covered telehealth, safe clinic reopening and Department of Health & Human Services loans.
Doctors Detail Kawasaki-Like Disease in Adult COVID-19 Patients
(Reuters Health)—During the COVID-19 pandemic, an inflammatory condition similar to Kawasaki disease has been reported in children and adolescents, and now two groups of New York doctors each describe a case, one in a 36-year-old woman and one in a 45-year-old man.1 “We’re still learning how COVID-19 is affecting children and adults. The better we…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…
Telemedicine & Fellowship Education After COVID-19: Q&A with Kanika Monga, MD
The COVID-19 pandemic is reshaping clinical rheumatology and the fellowship experience. Rheumatology education should include how to triage patients for remote visits, says second-year fellow Kanika Monga, MD…
FDA Approves Canakinumab for Adult-Onset Still’s Disease
Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 309
- Next Page »